FindTrial
Sign In

mRNA-1273.222

BIOLOGICAL4 trials

Sponsors

ModernaTX, Inc., National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

COVID-19SARS-CoV-2

Phase 1

Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines
CompletedNCT04889209
National Institute of Allergy and Infectious Diseases (NIAID)COVID-19
Start: 2021-05-28End: 2023-06-16Updated: 2025-04-20

Phase 2

A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19
CompletedNCT04649151
ModernaTX, Inc.SARS-CoV-2
Start: 2020-12-09End: 2024-06-14Updated: 2025-09-15
A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants
CompletedNCT04927065
ModernaTX, Inc.SARS-CoV-2
Start: 2021-05-28End: 2023-11-17Updated: 2025-02-28

Phase 3

A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19
CompletedNCT05815498
ModernaTX, Inc.COVID-19
Start: 2023-03-28End: 2025-04-12Updated: 2025-05-07

Related Papers

Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine.
2025-10-011 citations
Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trial.
2025-07-077 citations
P-102. Six-Month Safety, Durability, and Cross-Neutralization of the SARS-CoV-2 XBB.1.5-Containing Vaccine
Open Forum Infectious Diseases2025-01-29
Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescents
Human Vaccines & Immunotherapeutics2025-01-212 citations
Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain and N-Terminal Domain mRNA Vaccine
The Journal of Infectious Diseases2025-01-1010 citations
Safety and immunogenicity of a single-dose omicron-containing COVID-19 vaccination in adolescents: an open-label, single-arm, phase 2/3 trial.
2024-09-241 citations
The Novavax Heterologous Coronavirus Disease 2019 Booster Demonstrates Lower Reactogenicity Than Messenger RNA: A Targeted Review.
2024-08-0111 citations
Safety and durability of mRNA-1273-induced SARS-CoV-2 immune responses in adolescents: results from the phase 2/3 TeenCOVE trial.
2024-07-185 citations
Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results
Nature Medicine2023-08-3168 citations
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19.
2023-08-2320 citations
Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants.
2023-07-1118 citations
Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial.
2022-10-06121 citations
A Bivalent Omicron-Containing Booster Vaccine against Covid-19
New England Journal of Medicine2022-09-16635 citations
Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant.
2022-06-20139 citations
Homologous and Heterologous Covid-19 Booster Vaccinations
New England Journal of Medicine2022-01-26603 citations
Coronavirus disease 2019 vaccine for children in China: when to start? Mandatory or voluntary?
Chinese Medical Journal2021-09-214 citations
Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial.
2021-09-15137 citations
Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents
New England Journal of Medicine2021-08-11360 citations